BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3087695)

  • 1. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants.
    Odlind V; Olsson SE
    Contraception; 1986 Mar; 33(3):257-61. PubMed ID: 3087695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
    Olsson SE; Odlind V; Johansson ED; Nordström ML
    Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.
    Haukkamaa M
    Contraception; 1986 Jun; 33(6):559-65. PubMed ID: 3095023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
    Sivin I; Lähteenmäki P; Mishell DR; Alvarez F; Diaz S; Ranta S; Grozinger C; Lacarra M; Brache V; Pavez M; Nash H; Stern J
    Contraception; 1997 Nov; 56(5):317-21. PubMed ID: 9437561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
    Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in contraception: Norplant subdermal implant.
    Lynn MM; Holdcroft C
    Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
    Alvarez F; Brache V; Tejada AS; Cochon L; Faundes A
    Contraception; 1998 Oct; 58(4):211-4. PubMed ID: 9866001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study.
    Olsson SE
    Acta Obstet Gynecol Scand Suppl; 1987; 142():1-45. PubMed ID: 3116821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.
    Affandi B; Cekan SZ; Boonkasemsanti W; Samil RS; Diczfalusy E
    Contraception; 1987 Feb; 35(2):135-45. PubMed ID: 3109803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norplant: subdermal implant system for long-term contraception.
    Shoupe D; Mishell DR
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1286-92. PubMed ID: 2497646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norplant implants: the mechanism of contraceptive action.
    Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
    Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen levels in women using Norplant implants.
    Olsson SE; Odlind V; Johansson E
    Contraception; 1986 Aug; 34(2):157-67. PubMed ID: 2946553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
    Croxatto HB; Díaz S; Pavez M; Brandeis A
    Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
    Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
    Sivin I; Campodonico I; Kiriwat O; Holma P; Diaz S; Wan L; Biswas A; Viegas O; el din Abdalla K; Anant MP; Pavez M; Stern J
    Hum Reprod; 1998 Dec; 13(12):3371-8. PubMed ID: 9886517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.